Novavax/$NVAX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Novavax
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.
Ticker
$NVAX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
952
ISIN
US6700024010
Website
Novavax Metrics
BasicAdvanced
$1B
2.11
$2.99
3.21
-
Price and volume
Market cap
$1B
Beta
3.21
52-week high
$17.81
52-week low
$5.01
Average daily volume
11M
Financial strength
Current ratio
2.056
Quick ratio
1.783
Long term debt to equity
-295.045
Total debt to equity
-302.287
Interest coverage (TTM)
19.68%
Profitability
EBITDA (TTM)
473.771
Gross margin (TTM)
58.37%
Net profit margin (TTM)
38.14%
Operating margin (TTM)
34.19%
Effective tax rate (TTM)
2.06%
Revenue per employee (TTM)
$1,320,000
Management effectiveness
Return on assets (TTM)
19.97%
Return on equity (TTM)
-101.56%
Valuation
Price to earnings (TTM)
2.11
Price to revenue (TTM)
0.789
Price to book
-13.49
Price to tangible book (TTM)
-5.44
Price to free cash flow (TTM)
-4.997
Free cash flow yield (TTM)
-20.01%
Free cash flow per share (TTM)
-126.07%
Growth
Revenue change (TTM)
25.92%
Earnings per share change (TTM)
-185.53%
3-year revenue growth (CAGR)
-3.65%
10-year revenue growth (CAGR)
43.85%
3-year earnings per share growth (CAGR)
-44.55%
10-year earnings per share growth (CAGR)
-9.38%
What the Analysts think about Novavax
Analyst ratings (Buy, Hold, Sell) for Novavax stock.
Bulls say / Bears say
Novavax's COVID-19 vaccine, Nuvaxovid, received FDA approval for individuals aged 65 and older, expanding its market reach and potentially boosting sales. (reuters.com)
The company reported a significant financial turnaround in Q1 2025, posting $519 million in net income and $667 million in revenue, surpassing analyst expectations. (reuters.com)
Novavax secured a $1.2 billion licensing agreement with Sanofi for distribution rights in major markets, providing a substantial financial boost and enhancing its global presence. (reuters.com)
The FDA requested Novavax to conduct an additional clinical trial for its COVID-19 vaccine, potentially delaying full approval and increasing costs. (reuters.com)
U.S. Health and Human Services Secretary Robert F. Kennedy Jr. raised concerns about the efficacy of Novavax's COVID-19 vaccine, leading to a significant drop in the company's stock price. (reuters.com)
Novavax announced plans to cut about 25% of its global workforce, indicating potential financial challenges and operational downsizing. (bloomberg.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jun 2025.
Novavax Financial Performance
Revenues and expenses
Novavax Earnings Performance
Company profitability
Novavax News
AllArticlesVideos
Novavax's COVID-flu combo and standalone flu shots improve immunity in late-stage study
Reuters·1 week ago
Vaccine stocks muted as Wall Street takes 'wait and watch' approach after Kennedy's shake-up
Reuters·1 week ago
Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors.
Barrons·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Novavax stock?
Novavax (NVAX) has a market cap of $1B as of June 20, 2025.
What is the P/E ratio for Novavax stock?
The price to earnings (P/E) ratio for Novavax (NVAX) stock is 2.11 as of June 20, 2025.
Does Novavax stock pay dividends?
No, Novavax (NVAX) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Novavax dividend payment date?
Novavax (NVAX) stock does not pay dividends to its shareholders.
What is the beta indicator for Novavax?
Novavax (NVAX) has a beta rating of 3.21. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.